Command Palette

Search for a command to run...

Clinical Trials · NCT06352411

A Study to Test How BI 456906 is Taken up in the Blood of People With and Without Kidney Problems

CompletedPhase 1Survodutide (Approved)
Phase
Phase 1
Recruitment status
Completed
Sponsor
Boehringer Ingelheim
Enrollment
42
Start date
May 2024
Locations
2 sites, Germany
Primary endpoint
Area under the concentration-time curve of BI 456906 in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz)
View Survodutide compound reference